2009
DOI: 10.1016/j.ccr.2009.02.025
|View full text |Cite
|
Sign up to set email alerts
|

Optimization of cisplatin for the treatment of hormone dependent tumoral diseases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
34
0
4

Year Published

2010
2010
2019
2019

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 95 publications
(39 citation statements)
references
References 131 publications
0
34
0
4
Order By: Relevance
“…The clinical success of platinum-based drugs as anticancer agents is severely affected by the serious side effects, toxicity and acquired drug resistance [4][5][6]. These drawbacks drive inorganic chemists to develop innovative strategies for the preparation of more effective, less toxic, target specific and preferably non-covalently bound anticancer drugs.…”
Section: Introductionmentioning
confidence: 99%
“…The clinical success of platinum-based drugs as anticancer agents is severely affected by the serious side effects, toxicity and acquired drug resistance [4][5][6]. These drawbacks drive inorganic chemists to develop innovative strategies for the preparation of more effective, less toxic, target specific and preferably non-covalently bound anticancer drugs.…”
Section: Introductionmentioning
confidence: 99%
“…Schonenberger and co-authors have reported upon the ability of ethylenediamine derivatives and their Pt(II) complexes to bind to estrogen receptors, being active against hormone-dependent mammary carcinoma resistant to cisplatin (25)(26)(27)(28)(29).…”
Section: Resultsmentioning
confidence: 99%
“…As we are known, Cisplatin and its derivatives are the most widely used metal-based drug for cancer therapy, but their use is restricted by serious side effects, general toxicity, and acquired drug resistance [8][9][10][11][12][13][14]. These drawbacks drive inorganic chemists to develop innovative strategies for the preparation of more effective, less toxic, target specific, and preferably noncovalently bound anticancer drugs.…”
Section: Introductionmentioning
confidence: 99%